Answers are grounded in this paper and cite their sources.
PURPOSE OF REVIEW: Moyamoya is an important cause of stroke across the lifespan and accounts for up to 10% of pediatric ischemic strokes. Recent advances in genetic discovery, neuroimaging, surgical timing, and perioperative consensus have substantially changed the landscape of pediatric moyamoya care, necessitating a focused update for clinicians managing children with this disease. RECENT FINDINGS: Identification of RNF213 Arg4810Lys as the primary susceptibility variant and the role of a second-hit mechanism involving immune activation and hypoxia has advanced understanding of moyamoya pathogenesis and phenotypic heterogeneity. Multidelay ASL MRI has emerged as a valuable tool for perioperative perfusion assessment. A modified Delphi consensus established foundational perioperative care standards, while recent data highlight that surgical timing, postoperative hemodynamic management, and long-term neurocognitive and systemic outcomes remain critical gaps. SUMMARY: Surgical revascularization remains the mainstay of treatment and dramatically reduces stroke recurrence in children with moyamoya. Structured long-term surveillance encompassing neurocognitive assessment, mental health screening, and systemic comorbidity monitoring should be implemented as standard of care, as outcomes extend well beyond stroke prevention.
No takes yet. Share an insight, caveat, or question.
Chrisoula Cheronis (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: